1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Subcutaneous Self-Administration Markets to 2022 : Drugs, Devices, Therapeutics, Markets and Forecasts

As healthcare markets continue to evolve, drug developers and their supply chain partners are attempting to keep pace by addressing economic, market and therapeutic factors that increasingly revolve around how, when and where drugs are administered. This evolution is being driven by new and exciting options for patient care in the form of powerful drug therapies for treating diseases with improved outcomes and for treating diseases for which an effective treatment did not previously exist. Beyond oncology –where therapeutics continue to be supplied for administration via infusion – the majority of new non-oral drugs are being formulated for subcutaneous injection. Many of these drugs are indicated for chronic conditions, which because of the continuous need for dosing over time benefit significantly when patients can self-administer their medication. This report examines in detail the drugs, devices, therapeutics and markets that are set to change substantially over the remainder of the decade.

Highlights

- Provides detailed analysis of self-administered subcutaneous drug products, drug delivery and device strategies, and product development factors
- Assesses key markets, market dynamics and market demographics
- Analyzes therapeutic demand drivers and evaluates SC drug products in nine key therapeutic segments
- Provides market data and forecasts to 2022
- Profiles market sector participants, their product development activities, business strategies, and corporate alliances and affiliations
- Assesses the importance of alliances and partnerships on self-administered subcutaneous drug product commercialization
- Evaluates the impact of economic, technology, and regulatory factors

Table Of Contents

Subcutaneous Self-Administration Markets to 2022 : Drugs, Devices, Therapeutics, Markets and Forecasts
Executive Summary

Subcutaneous Drug Delivery - Market Dynamics

Subcutaneous Delivery - Why it's Growing
The Evolving Drug Pipeline
Device and Packaging Technology Advances
Shifting Patient Demographics
Healthcare Economics
Demand Drivers
The Trend toward Self-Administration
Innovation in Prefilled Device Designs
Therapeutic Targets and Treatment
Competitive Landscape
Risk Factors

SC Delivery Device Design Factors

Ergonomics and Ease of Use
Safety Features
Needle Shielding
Needle Insertion Depth
Failsafe Activation
Dose Inspection/Injection Confirmation
Lyophilized Drugs/Reconstitution

Subcutaneously Delivered Drugs - Delivery Device Strategies

Delivering Self-Administered SC Drugs
Handheld Devices
Autoinjectors
Pen Injectors
Prefilled Syringes
Other Handheld Devices
Wearable Devices
Patch Pumps
Large Volume Wearable Devices

SC Self-Administration - Product Analysis and Forecasts by Therapeutic Sector

Anticoagulants
Antivirals
Autoimmune Diseases
Diabetes
Hematopoietics
Hormone Replacement
Neurology
Osteoporosis
Reproductive Health

Market Factors

Regulatory Issues
DTC Marketing
Patient Education

Company Profiles

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Assessment to 2025

PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Assessment to 2025

  • $ 10995
  • Industry report
  • October 2016
  • by Global Data

PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Assessment to 2025 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. It is characterized ...

Colorectal Cancer KOL Insight 2016

Colorectal Cancer KOL Insight 2016

  • $ 8085
  • Industry report
  • October 2016
  • by Firstword Pharma

KOLs embrace novel MoAs as low survival rates drive search for new treatments Faced with persistently low survival rates, KOLs are calling for new approaches to treat late-stage colorectal cancer (CRC). ...

Frontier Pharma: Hepatitis C - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations

Frontier Pharma: Hepatitis C - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations

  • $ 6995
  • Industry report
  • December 2016
  • by GBI Research

Frontier Pharma: Hepatitis C - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations Summary Hepatitis C is a blood-borne viral infection ...


Download Unlimited Documents from Trusted Public Sources

Biguanide Market

  • January 2017
    8 pages
  • Biguanide  

    Genetic  

    Chromosome  

View report >

Biological Therapy Industry in the US

  • January 2017
    9 pages
  • Vaccine  

  • United States  

View report >

Therapy Market in the UK

  • January 2017
    19 pages
  • Therapy  

  • United Kingdom  

View report >

Related Market Segments :

Therapy

ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.